What is the outlook for China's ampicillin production capacity amid ongoing industry consolidation?

What is the outlook for China's ampicillin production capacity amid ongoing industry consolidation?
China's ampicillin production landscape is undergoing structural adjustment. The relocation and upgrade project at Shandong Lukang, a major penicillin producer, illustrates the trend: it maintains ampicillin sodium capacity at just 20 t/a while introducing piperacillin sodium at 160 t/a and mezlocillin sodium at 50 t/a. This rebalancing reflects margin pressure in ampicillin, where enzyme-based processes quote around RMB 235/kg versus chemical synthesis at RMB 250-260/kg. Meanwhile, new veterinary-focused capacity is emerging, such as Shandong Qihui Chemical's project producing 180 t/a of ampicillin sodium for animal health. The overall direction is clear: human-grade ampicillin capacity is being rationalized and consolidated, while veterinary-grade production expands to serve livestock demand. This dual-track development means buyers should expect tighter supply for pharmaceutical-grade material but ample availability for veterinary applications, with pricing diverging accordingly.